CPI-0610 is a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies.
choosing a selection results in a full page refresh
Product has been added to your wishlist.
You can view your wishlist by creating or login account.
Please create account through ##customer_email## email
